Comparative Pharmacology
Head-to-head clinical analysis: MIDAZOLAM versus XANAX.
Peer-Reviewed Evidence
Head-to-head clinical analysis: MIDAZOLAM versus XANAX.
MIDAZOLAM vs XANAX
Comparing the clinical profiles, pharmacokinetic behaviors, and safety indices of these two therapeutic agents.
Midazolam is a benzodiazepine that potentiates gamma-aminobutyric acid (GABA) activity by binding to the benzodiazepine site on GABA-A receptors, enhancing GABA's inhibitory effects, leading to increased chloride ion conductance, hyperpolarization, and neuronal inhibition.
Alprazolam is a benzodiazepine that binds to the gamma-aminobutyric acid (GABA)-A receptor at the α1, α2, α3, and α5 subunits, enhancing the effect of GABA by increasing chloride ion conductance, leading to neuronal hyperpolarization and inhibition of neurotransmission.
IV: 0.5-2 mg initial, titrate by 0.5-1 mg increments every 2-3 min; typical total 2.5-5 mg. IM: 0.07-0.08 mg/kg (usual 5 mg). Oral: 7.5-15 mg as a single premedication dose.
Initial: 0.25-0.5 mg orally 3 times daily; maximum: 4 mg/day in divided doses. For panic disorder: 0.5-1 mg at bedtime or 0.5 mg 3 times daily; titrate as needed up to 10 mg/day.
None Documented
None Documented
Clinical Note
moderateMidazolam + Fluticasone propionate
"The risk or severity of adverse effects can be increased when Midazolam is combined with Fluticasone propionate."
Clinical Note
moderateMidazolam + Sulfisoxazole
"The metabolism of Sulfisoxazole can be decreased when combined with Midazolam."
Clinical Note
moderateMidazolam + Erythromycin
"The serum concentration of Erythromycin can be increased when it is combined with Midazolam."
Clinical Note
moderateMidazolam + Cyclosporine
Terminal elimination half-life: 1.5-2.5 hours in healthy adults; prolonged in elderly (5-6 hours), obesity, hepatic cirrhosis (up to 20 hours), and critical illness.
Terminal elimination half-life: 11.2 hours (range 6.3–26.9 hours). With repeated dosing, half-life may prolong slightly; clinical context: allows once-daily dosing for most patients.
Renal: approximately 45-57% as metabolites (primarily 1-hydroxymidazolam glucuronide) and <1% unchanged; fecal: 2-10% via biliary excretion.
Renal: ~80% (mainly as glucuronide metabolites, <20% unchanged). Fecal: <7%.
Category D/X
Category C
Benzodiazepine
Benzodiazepine
"The metabolism of Cyclosporine can be decreased when combined with Midazolam."